Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
The Fed’s September rate cut turbo-charged the stock market, but can the market keep up its bull run for 2025?
The massive private-equity investments are causing concerns about its impact on the wealth management industry.
New filings with the Securities and Exchange Commission are requesting permission to launch ETFs that hold both public and private assets.